Header Logo

Connection

Diego Cadavid to Female

Back to Details
This is a "connection" page, showing publications Diego Cadavid has written about Female.
Diego Cadavid
Connection Strength
0.643
Female
  1. Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulovic J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019 09; 18(9):845-856.
    View in: PubMed
    Score: 0.036
  2. Petrillo J, Balcer L, Galetta S, Chai Y, Xu L, Cadavid D. Initial Impairment and Recovery of Vision-Related Functioning in Participants With Acute Optic Neuritis From the RENEW Trial of Opicinumab. J Neuroophthalmol. 2019 06; 39(2):153-160.
    View in: PubMed
    Score: 0.036
  3. Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, Ziemssen F, Massacesi L, Chai Y, Xu L, Freeman S. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017 Mar; 16(3):189-199.
    View in: PubMed
    Score: 0.031
  4. Goldman MD, Ward MD, Motl RW, Jones DE, Pula JH, Cadavid D. Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale. Mult Scler. 2017 Sep; 23(10):1405-1414.
    View in: PubMed
    Score: 0.030
  5. Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. 2017 01; 23(1):94-105.
    View in: PubMed
    Score: 0.029
  6. Motl RW, Putzki N, Pilutti LA, Cadavid D. Longitudinal changes in self-reported walking ability in multiple sclerosis. PLoS One. 2015; 10(5):e0125002.
    View in: PubMed
    Score: 0.027
  7. Goldman MD, Motl RW, Scagnelli J, Pula JH, Sosnoff JJ, Cadavid D. Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world. Neurology. 2013 Nov 19; 81(21):1856-63.
    View in: PubMed
    Score: 0.024
  8. Learmonth YC, Motl RW, Sandroff BM, Pula JH, Cadavid D. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol. 2013 Apr 25; 13:37.
    View in: PubMed
    Score: 0.024
  9. Cadavid D, Jurgensen S, Lee S. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. PLoS One. 2013; 8(1):e53297.
    View in: PubMed
    Score: 0.023
  10. Johnson MA, Cadavid D. Simvastatin in acute optic neuritis. Mult Scler. 2012 Nov; 18(11):1657; author reply 1658.
    View in: PubMed
    Score: 0.022
  11. Cheriyan J, Kim S, Wolansky LJ, Cook SD, Cadavid D. Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol. 2012 Jan; 69(1):82-8.
    View in: PubMed
    Score: 0.022
  12. Cadavid D, Kim S, Peng B, Skurnick J, Younes M, Hill J, Wolansky LJ, Cook SD. Clinical consequences of MRI activity in treated multiple sclerosis. Mult Scler. 2011 Sep; 17(9):1113-21.
    View in: PubMed
    Score: 0.021
  13. Londo?o D, Cadavid D. Bacterial lipoproteins can disseminate from the periphery to inflame the brain. Am J Pathol. 2010 Jun; 176(6):2848-57.
    View in: PubMed
    Score: 0.019
  14. Mehra R, Londo?o D, Sondey M, Lawson C, Cadavid D. Structure-function investigation of vsp serotypes of the spirochete Borrelia hermsii. PLoS One. 2009 Oct 30; 4(10):e7597.
    View in: PubMed
    Score: 0.019
  15. Festa ED, Hankiewicz K, Kim S, Skurnick J, Wolansky LJ, Cook SD, Cadavid D. Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult Scler. 2009 Nov; 15(11):1271-9.
    View in: PubMed
    Score: 0.018
  16. Londo?o D, Carvajal J, Arguelles-Grande C, Marques A, Cadavid D. Interleukin 10 protects the brain microcirculation from spirochetal injury. J Neuropathol Exp Neurol. 2008 Oct; 67(10):976-83.
    View in: PubMed
    Score: 0.017
  17. Londo?o D, Marques A, Hornung RL, Cadavid D. Relapsing fever borreliosis in interleukin-10-deficient mice. Infect Immun. 2008 Dec; 76(12):5508-13.
    View in: PubMed
    Score: 0.017
  18. Londo?o D, Marques A, Hornung RL, Cadavid D. IL-10 helps control pathogen load during high-level bacteremia. J Immunol. 2008 Aug 01; 181(3):2076-83.
    View in: PubMed
    Score: 0.017
  19. Cadavid D, Garcia E, Gelderblom H. Coinfection with Borrelia turicatae serotype 2 prevents the severe vestibular dysfunction and earlier mortality caused by serotype 1. J Infect Dis. 2007 Jun 01; 195(11):1686-93.
    View in: PubMed
    Score: 0.016
  20. Sethi N, Sondey M, Bai Y, Kim KS, Cadavid D. Interaction of a neurotropic strain of Borrelia turicatae with the cerebral microcirculation system. Infect Immun. 2006 Nov; 74(11):6408-18.
    View in: PubMed
    Score: 0.015
  21. Cadavid D, Sondey M, Garcia E, Lawson CL. Residual brain infection in relapsing-fever borreliosis. J Infect Dis. 2006 May 15; 193(10):1451-8.
    View in: PubMed
    Score: 0.014
  22. Londo?o D, Bai Y, Z?ckert WR, Gelderblom H, Cadavid D. Cardiac apoptosis in severe relapsing fever borreliosis. Infect Immun. 2005 Nov; 73(11):7669-76.
    View in: PubMed
    Score: 0.014
  23. Tawil R, Wagner KR, Hamel JI, Leung DG, Statland JM, Wang LH, Genge A, Sacconi S, Lochm?ller H, Reyes-Leiva D, Diaz-Manera J, Alonso-Perez J, Muelas N, Vilchez JJ, Pestronk A, Gibson S, Goyal NA, Hayward LJ, Johnson N, LoRusso S, Freimer M, Shieh PB, Subramony SH, van Engelen B, Kools J, Leinhard OD, Widholm P, Morabito C, Moxham CM, Cadavid D, Mellion ML, Odueyungbo A, Tracewell WG, Accorsi A, Ronco L, Gould RJ, Shoskes J, Rojas LA, Jiang JG. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2024 May; 23(5):477-486.
    View in: PubMed
    Score: 0.013
  24. Widholm P, Ahlgren A, Karlsson M, Romu T, Tawil R, Wagner KR, Statland JM, Wang LH, Shieh PB, van Engelen BGM, Cadavid D, Ronco L, Odueyungbo AO, Jiang JG, Mellion ML, Dahlqvist Leinhard O. Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole-body fat-referenced MRI: Protocol development, multicenter feasibility, and repeatability. Muscle Nerve. 2022 08; 66(2):183-192.
    View in: PubMed
    Score: 0.011
  25. DeBevits JJ, Munbodh R, Bageac D, Wu R, DiCamillo PA, Hu C, Wang L, Naismith RT, Karimeddini D, Dhib-Jalbut S, Redko S, Cook SD, Cadavid D, Wolansky L. Gray Matter Nucleus Hyperintensity After Monthly Triple-Dose Gadopentetate Dimeglumine With Long-term Magnetic Resonance Imaging. Invest Radiol. 2020 10; 55(10):629-635.
    View in: PubMed
    Score: 0.010
  26. Nolan RC, Galetta SL, Frohman TC, Frohman EM, Calabresi PA, Castrillo-Viguera C, Cadavid D, Balcer LJ. Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis. J Neuroophthalmol. 2018 12; 38(4):451-458.
    View in: PubMed
    Score: 0.009
  27. Klistorner A, Chai Y, Leocani L, Albrecht P, Aktas O, Butzkueven H, Ziemssen T, Ziemssen F, Frederiksen J, Xu L, Cadavid D. Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. CNS Drugs. 2018 12; 32(12):1159-1171.
    View in: PubMed
    Score: 0.009
  28. Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdov? EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018 05; 17(5):405-415.
    View in: PubMed
    Score: 0.008
  29. Fern?ndez R, Cardona JA, Cadavid D, ?lvarez LG, Restrepo FA. Survival of Endodontically Treated Roots/Teeth Based on Periapical Health and Retention: A 10-year Retrospective Cohort Study. J Endod. 2017 Dec; 43(12):2001-2008.
    View in: PubMed
    Score: 0.008
  30. Maranzano J, Rudko DA, Nakamura K, Cook S, Cadavid D, Wolansky L, Arnold DL, Narayanan S. MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis. Neurology. 2017 Aug 15; 89(7):714-721.
    View in: PubMed
    Score: 0.008
  31. Brown RA, Narayanan S, Stikov N, Cook S, Cadavid D, Wolansky L, Arnold DL. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon ?-1b. Neurology. 2016 Aug 30; 87(9):905-11.
    View in: PubMed
    Score: 0.007
  32. Wolansky LJ, Cadavid D, Punia V, Kim S, Cheriyan J, Haghighi M, Cook SD. Hypophosphatemia is Associated with the Serial Administration of Triple-Dose Gadolinium to Patients for Brain MRI. J Neuroimaging. 2015 May-Jun; 25(3):379-83.
    View in: PubMed
    Score: 0.007
  33. Magistrale G, Pisani V, Argento O, Incerti CC, Bozzali M, Cadavid D, Caltagirone C, Medori R, DeLuca J, Nocentini U. Validation of the World Health Organization Disability Assessment Schedule II (WHODAS-II) in patients with multiple sclerosis. Mult Scler. 2015 Apr; 21(4):448-56.
    View in: PubMed
    Score: 0.006
  34. Londo?o D, Cadavid D, Drouin EE, Strle K, McHugh G, Aversa JM, Steere AC. Antibodies to endothelial cell growth factor and obliterative microvascular lesions in the synovium of patients with antibiotic-refractory lyme arthritis. Arthritis Rheumatol. 2014 Aug; 66(8):2124-33.
    View in: PubMed
    Score: 0.006
  35. Erlanger DM, Kaushik T, Caruso LS, Benedict RH, Foley FW, Wilken J, Cadavid D, Deluca J. Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial. J Neurol Sci. 2014 May 15; 340(1-2):123-9.
    View in: PubMed
    Score: 0.006
  36. Edwards KR, Goyal J, Plavina T, Czerkowicz J, Goelz S, Ranger A, Cadavid D, Browning JL. Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis. PLoS One. 2013; 8(11):e81007.
    View in: PubMed
    Score: 0.006
  37. Motl RW, Cadavid D, Sandroff BM, Pilutti LA, Pula JH, Benedict RH. Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores. J Neurol Sci. 2013 Dec 15; 335(1-2):169-73.
    View in: PubMed
    Score: 0.006
  38. Fern?ndez R, Cadavid D, Zapata SM, Alvarez LG, Restrepo FA. Impact of three radiographic methods in the outcome of nonsurgical endodontic treatment: a five-year follow-up. J Endod. 2013 Sep; 39(9):1097-103.
    View in: PubMed
    Score: 0.006
  39. Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012 Nov; 72(5):779-87.
    View in: PubMed
    Score: 0.006
  40. Benedict RH, Smerbeck A, Parikh R, Rodgers J, Cadavid D, Erlanger D. Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: implications for multiple sclerosis clinical trials. Mult Scler. 2012 Sep; 18(9):1320-5.
    View in: PubMed
    Score: 0.005
  41. Qian P, Cadavid D, Wolansky LJ, Cook SD, Naismith RT. Heterogeneity in longitudinal evolution of ring-enhancing multiple sclerosis lesions. Ann Neurol. 2011 Oct; 70(4):668-9; author reply 669-70.
    View in: PubMed
    Score: 0.005
  42. Pachner AR, Cadavid D, Wolansky L, Skurnick J. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology. 2009 Nov 03; 73(18):1485-92.
    View in: PubMed
    Score: 0.005
  43. Mena H, Cadavid D, Rushing EJ. Human cerebral infarct: a proposed histopathologic classification based on 137 cases. Acta Neuropathol. 2004 Dec; 108(6):524-30.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.